Ключевые слова
Как цитировать
Аннотация
Медуллобластома - наиболее распространенная злокачественная опухоль центральной нервной системы у детей, клинические проявления, ответ на проводимую терапию и прогноз которой значительно вариабельны. В многочисленных работах была продемонстрирована прогностическая значимость различных клинических, морфологических, цитогенетических и молекулярно-биологических характеристик заболевания. С внедрением в исследовательскую практику высокопроизводительных молекулярно-генетических технологий удалось идентифицировать четыре независимые подгруппы медуллобластомы, имеющие различный источник гистогенеза, молекулярный патогенез, клинические проявления и исход. Данный обзор посвящен молекулярно-биологическим свойствам медуллобластомы, лежащим в основе ее клинической гетерогенности и создающим основы стратификации пациентов для проведения риск-адаптированного и таргетного лечения.Библиографические ссылки
Beachy P.A., Hymowitz S.G., Lazarus R.A. et al. Interactions between Hedgehog proteins and their binding partners come into view // Genes. Dev. - 2010. - Vol. 24. - № 18. - P. 2001-2012.
Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer // Nat. Rev. Cancer. - 2012. - Vol. 12. - № 7. - P. 465-477.
Briscoe J., Therond P.P. The mechanisms of Hedgehog signalling and its roles in development and disease // Nat. Rev. Mol. Cell. Biol. - 2013. - Vol. 14. - № 7. - P. 416-429.
Cadigan K.M. TCFs and Wnt/p-catenin signaling: more than one way to throw the switch // Curr. Top. Dev. Biol. - 2012. - Vol. 98. - P. 1-34.
Chen H.J., Hsu L.S., Shia YT. et al. The p-catenin/TCF complex as a novel target of resveratrol in the Wnt/pcatenin signaling pathway // Biochem Pharmacol. - 2012. - Vol. 84. - №. 9. - P. 1143-1153.
Cimmino F, Scoppettuolo M.N., Carotenuto M. et al. Nor-cantharidin impairs medulloblastoma growth by inhibition of Wnt/-catenin signaling // J. Neurooncol. - 2012. - Vol. 106. - № 1. - P. 59-70.
Clifford S.C., Lusher M.E., Lindsey J.C. et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblasto-mas associated with a favorable prognosis // Cell Cycle. - 2006. - Vol. 5. - №. 22. - P. 2666-2670.
Clifford S.C., Lannering B., Schwalbe E.C. et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial // Oncotarget. - 2015. - Vol. 6. - № 36. - P. 38827-38839.
Coluccia D., Figuereido C., Isik S. et al. Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm // Curr Neurol Neurosci Rep. - 2016. - Vol. 16. - № 5. - P. 43-54.
Cruciat C.M., Dolde C., de Groot R.E. et al. RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-p-catenin signaling // Science. - 2013. - Vol. 339. - № 6126. - P. 1436-1441.
Dhall G. Medulloblastoma // J. Child Neurol. - 2009. -Vol. 24. - № 11. - P. 1418-1430.
Ellison D.W., Onilude O.E., Lindsey J.C. et al. beta-Catenin status predicts a favorable outcome in childhood medul-loblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee // J. Clin. Oncol. - 2005. - Vol. 23. - № 31. - P. 7951-7957.
Ellison D.W., Dalton J., Kocak M. et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and nonSHH/WNT molecular subgroups // Acta. Neuropathol. - 2011. - Vol. 121. - № 3. - P. 381-396.
Ellison D.W., Kocak M., Dalton J. et al. Definition of dis-ease-risk stratification groups in childhood medulloblas-toma using combined clinical, pathologic, and molecular variables // J. Clin. Oncol. - 2011. - Vol. 29. - № 11. - P. 400-407.
Evans G., Burnell L., Campbell R. et al.Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma // Med. Pediatr. Oncol. - 1993. - Vol. 21. - № 6. - P. 433-434.
Falkenstein K.N., Vokes S.A. Transcriptional regulation of graded Hedgehog signaling // Semin. Cell Dev. Biol. - 2014. - № 33. - P. 73-80.
Gajjar A., Hernan R., Kocak M. et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma // J. Clin. Oncol. - 2004. - Vol. 22. - № 6. - P. 984-993.
Gajjar A., Chintagumpala M., Ashley D. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial // Lancet Oncol. - 2006. - Vol. 7. - № 10. - P. 813-820.
Gajjar A., Stewart C.F, Ellison D.W. et al. Phase I study of vismodegib in children with recurrent or refractory me-dulloblastoma: a pediatric brain tumor consortium study // Clin. Cancer Res. - 2013. - Vol. 19. - № 22. - P. 6305-6312.
Gajjar A.J., Robinson G.W. Medulloblastoma-translating discoveries from the bench to the bedside // Nat. Rev. Clin. Oncol. - 2014. - Vol. 11. - № 12. - P. 714-722.
Gajjar A., Bowers D.C., Karajannis M.A. et al. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape // J. Clin. Oncol. - 2015. - Vol. 33. - № 27. - P. 2986-2998.
Gibson P., Tong Y, Robinson G. et al. Subtypes of medulloblastoma have distinct developmental origins // Nature. - 2010. - Vol. 468. - № 7327. - P. 1095-1099.
Geiss G.K., Bumgarner R.E., Birditt B. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs // Nat. Biotechnol. - 2008. - Vol. 26. - № 3. - P. 317-325.
Gilbertson R.J., Perry R.H., Kelly P.J. et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma // Cancer Res. - 1997. - Vol. 57. - № 15. - P. 3272-3280.
Gilbertson R., Wickramasinghe C., Hernan R. et al. Clinical and molecular stratification of disease risk in medul-loblastoma // Br. J. Cancer. - 2001. - Vol. 85. - № 5. - P. 705-712.
Gougelet A., Colnot S. A Complex Interplay between Wnt/ p-Catenin Signalling and the Cell Cycle in the Adult Liver // Int. J. Hepatol. - 2012. - Vol. 2012. - P. 1-7.
Grotzer M.A., Janss A.J., Phillips PC., Trojanowski J.Q. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors // Klin. Padiatr. - 2000. - Vol. 212. - № 4. - P. 196-199.
Grotzer M.A., Hogart M.D., Janss A.J. et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma // Clin. Cancer Res. - 2001. - Vol. 7. - № 8. - P 24252433.
Hadjihannas M.V., Bernkopf D.B., Bruckner M., Behrens J. Cell cycle control of Wnt/p-catenin signalling by conductin/axin2 through CDC20 // EMBO Rep. - 2012. - Vol.13. - № 4. - P. 347-354.
Hamilton S.R., Liu B., Parsons R.E. et al.The molecular basis of Turcot's syndrome // N. Engl. J. Med. - 1995. - Vol. 332. - № 13. - P. 839-847.
Hovestadt V., Remke M., Kool M. et al. Robust molecular subgrouping and copy-number profiling of medulloblasto-ma from small amounts of archival tumour material using high-density DNA methylation arrays // Acta Neuropathol. - 2013. - Vol. 125. - № 6. - P. 913-916.
Hui C.C., Angers S. Gli proteins in development and disease // Annu. Rev. Cell Dev. Biol. - 2011. - Vol. 27. - P. 513-537.
Jones D.T., Jager N., Kool M. et al. Dissecting the genomic complexity underlying medulloblastoma // Nature. - 2012. - Vol. 488. - № 7409. - P. 100-105.
Jozwiak J., Grajkowska W., Wlodarski P. Pathogenesis of medulloblastoma and current treatment outlook // Med. Res. Rev. - 2007. - Vol. 27. - № 6. - P. 869-890.
Komiya Y, Habas R. Wnt signal transduction pathways // Organogenesis. - 2008. - Vol. 4. - № 2. - P. 68-75.
Kool M., Korshunov A., Remke M. et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas // Acta. Neuropathol. - 2012. - Vol. 123. - № 4. - P. 473-484.
Kool M., Korshunov A., Pfister S.M. Update on molecular and genetic alterations in adult medulloblastoma // Memo. - 2012. - Vol. 5. - № 3. - P. 228-232.
Kool M., Jones D.T., Jageret N. al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition // Cancer Cell. - 2014. - Vol. 25. - № 3. - P. 393-405.
Lee M.J., Hatton B.A., Villavicencio E.H. et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model // Proc. Natl. Acad. Sci. USA. - 2012. - Vol. 109. - № 20. - P. 7859-7864.
Lin C.Y, Erkek S., Tong Y et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins // Nature. - 2016. - Vol. 530. - № 7588. - P. 57-62.
Louis D.N., Ohgaki H., Wiestler O.D. et al. The 2007 WHO classification of tumours of the central nervous system // Acta. Neuropathol. - 2007. - Vol. 114. - № 2. - P. 97-109.
Louis D.N., Perry A., Reifenberger G. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary // Acta Neuropathol. - 2016. - Vol. 131. - № 6. - P. 803-820.
Millard N.E., De Braganca K.C. Medulloblastoma // J. Child Neurol. - 2015. - Vol. 2. - P. 1-13.
Minde D.P., Anvarian Z., Rudiger S.G., Maurice M.M. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? // Mol. Cancer. - 2011. - Vol. 10. - P. 101-110.
Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer // Nat. Rev. Cancer. - 2011. - Vol. 11. - № 7. - P. 493-501.
Niehrs C. The complex world of WNT receptor signaling // Nat. Rev. Mol. Cell Biol. - 2012. - Vol. 13. - № 12. - P. 767-79.
Northcott P.A., Nakahara Y, Wu X. et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma // Nat Genet. - 2009. -Vol. 41. - № 4. - P. 465-472.
Northcott P.A., Korshunov A., Witt H. et al. Medulloblastoma comprises four distinct molecular variants // J. Clin. Oncol. - 2011. - Vol. 29. -№ 11. - P. 1408-1414.
Northcott P.A., Jones D.T., Kool M. et al. Medulloblastomics: the end of the beginning // Nat. Rev. Cancer. - 2012. -Vol. 12. - № 12. - P. 818-834.
Northcott P.A., Korshunov A., Pfister S.M., Taylor M.D. The clinical implications of medulloblastoma subgroups // Nat. Rev. Neurol. - 2012. - Vol. 8. - № 6. - P. 340-351.
Northcott P.A., Shih D.J., Remke M. et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples // Acta Neuropathol. - 2012. - Vol. 123. - № 4. - P. 615-626.
Northcott P.A., Shih D.J., Peacock J. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes // Nature. - 2012. - Vol. 488. - № 7409. - P. 49-56.
Northcott P.A., Lee C., Zichner T., Sttz A.M. et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma // Nature. - 2014. - Vol. 511. - № 7510. - P. 428-434.
Ostrom Q.T., de Blank P.M., Kruchko C. et al.c Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011 // Neuro Oncol. - 2015. - Vol. Suppl. 10. - P. 1-36.
Pan E., Pellarin M., Holmes E. et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients // Clin. Cancer Res. - 2005. -Vol. 11. - № 13. - P. 4733-4740.
Pfister S., Remke M., Benner A. et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci // J. Clin. Oncol. - 2009. - Vol. 27. - № 10. - P. 1627-1636.
Pietsch T., Schmidt R., Remke M. et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort // Acta Neuropathol. - 2014. - Vol. 128. - № 1. - P. 137-149.
Pugh T.J., Weeraratne S.D., Archer T.C. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations // Nature. - 2012. - Vol. 488. - № 7409. - P. 106-110.
Ransohoff K.J., Sarin K.Y, Tang J.Y Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma // J. Clin. Oncol. - 2015. - Vol. 33. - № 24. - P. 2692-2694.
Ray A., Ho M., Ma J. et al. A clinicobiological model predicting survival in medulloblastoma // Clin. Cancer Res. - 2004. - Vol. 10. - № 22. - P. 7613-7620.
Remke M., Hielscher T, Korshunov A. et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma // J. Clin. Oncol. - 2011. - Vol. 29. -№ 29. - P. 3852-3861.
Robinson G., Parker M., Kranenburg T.A. et al. Novel mutations target distinct subgroups of medulloblastoma // Nature. - 2012. - Vol. 488. - № 7409. - P. 43-48.
Robinson G.W., Orr B.A., Wu G. et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032 // J. Clin. Oncol. - 2015. - Vol. 33. - № 24. - P. 2646-2654.
Rutkowski S., Bode U., Deinlein F. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone // N. Engl. J. Med. - 2005. - Vol. 352. - № 10. - P. 978-986.
Sekulic A., Migden M.R., Oro A.E. et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma // N. Engl. J. Med. - 2012. - Vol. 366. - № 23. - P. 2171-2179.
Shih D.J., Northcott P.A., Remke M. et al. Cytogenetic prognostication within medulloblastoma subgroups // J. Clin. Oncol. - 2014. - Vol. 32. - № 9. - P. 886-896.
Slade I., Murray A., Hanks S. et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma // Fam. Cancer. - 2011. - Vol. 10. - № 2. - P. 337-342.
Tang Y, Gholamin S., Schubert S. et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition // Nat. Med. - 2014. - Vol. 20. - № 7. - P. 732-740.
Taylor M.D., Mainprize T.G., Rutka J.T. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review // Neurosurgery. - 2000. - Vol. 47. - № 4. - P. 888-901.
Taylor M.D., Liu L., Raffel C. et al. Mutations in SUFU predispose to medulloblastoma // Nat. Genet. - 2002. -Vol. 31. - № 3. - P. 306-310.
Taylor M.D., Northcott P.A., Korshunov A. et al. Molecular subgroups of medulloblastoma: the current consensus // Acta. Neuropathol. - 2012. - Vol. 123. - № 4. - P. 465472.
Teglund S., Toftg rd R. Hedgehog beyond medulloblastoma and basal cell carcinoma // Biochim. Biophys. Acta. -2010. - Vol. 1805. - № 2. - P. 181-208.
Thompson E.M., Whitney N.L., Wu YJ., Neuwelt E.A. The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma // J. Neurosurg. Pediatr. - 2013. - Vol. 11. - № 1. - P. 60-67.
Wilson C.W., Chuang P.T. Mechanism and evolution of cytosolic Hedgehog signal transduction // Development. - 2010. - Vol. 137. - № 13. - P. 2079-2094.
Zhukova N., Ramaswamy V., Remke M. et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma // J. Clin. Oncol. - 2013. - Vol. 31. -№ 23. - P. 2927-2935.
Zinke J., Schneider F.T., Harter P.N. et al. p-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma // Mol Cancer. - 2015. - Vol. 14. - № 1. - P. 17-26.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2017